Skip to main content
editorial
. 2021 Dec 28;27(48):8201–8215. doi: 10.3748/wjg.v27.i48.8201

Table 1.

Primary signaling pathways and relative drug applications of Crohn’s disease

Signaling pathway
Relative function
Targeted factor
Drug application
NF-κB Maintenance of epithelial integrity and intestinal immune homeostasis TNF-α infliximab, adalimumab, and certolizumab
IL-12/23 ustekinumab
IκBa corticosteroids
TGF-β/SMAD3 Immunosuppression and fibrosis SMAD7 mongerson
JAK/STAT Immunoregulation, anti-inflammation and epithelial barrier function JAK tofacitinib and filgotinib
Chemokines/integrins Leukocytes trafficking to targeted location α4β7 integrin vedolizumab
α4β7 and αEβ7 integrins etrolizumab
MAdCAM1 PF-00547659
Wnt Regulation of epithelial proliferation and gut mucosal homeostasis NA NA

NF-κB: Nuclear factor kappa B; TGF-β: Transforming growth factor-β; JAK: Janus kinase; STAT: Signal transducer and activator of transcription; Wnt: Wingless/Int1; TNF-α: Tumor necrosis factor-α; IL: Interleukin; NA: Not available.